Observational Survey of Adults with Urothelial Cancer Receiving PADCEV Injection in South Korea

What this Trial Is About

Researchers are observing adults in South Korea who have locally advanced or metastatic urothelial cancer, a type of bladder lining cancer. This study focuses on patients already prescribed PADCEV Injection enfortumab vedotin and aims to collect information about their treatment outcomes and any medical issues that arise during their care. The study is observational, meaning no new treatments are given as part of the trial, but data is gathered from routine clinical practice. Participants receive PADCEV Injection at doses of 20 mg or 30 mg according to their doctors standard care and the approved drug label. The study does not assign treatments but observes patients receiving this medication in real-world settings. Patients are monitored for up to 48 weeks after their first dose. If a patient stops taking PADCEV earlier, their records will be reviewed for up to 30 days after the last dose or until they start a different cancer medicine. During the study, medical records will be reviewed regularly to check the patients cancer condition and note any adverse events, including serious or unexpected side effects and risks. The study will also observe overall survival and progression-free survival up to 48 weeks. Participants will not have specific study visits beyond their normal care, and their health information will be collected through record review over the course of about one year.

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection